Drug Profile
BAR 704
Alternative Names: BAR704Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Bar Pharmaceuticals
- Class Antifibrotics; Hepatoprotectants
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatic fibrosis; Liver disorders
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Hepatic-fibrosis in Italy (Intraperitoneal)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Liver-disorders in Italy (Intraperitoneal)
- 06 May 2017 Preclinical trials in Hepatic fibrosis in Italy (Intraperitoneal) before May 2017